Monoammonium glycyrrhizinate hydrate

53956-04-0

C42H65NO16

DMSO : >= 100 mg/mL (119.05 mM)

Others

Monoammonium glycyrrhizinate hydrate has various pharmacological actions such as anti-inflammatory, antiallergic, antigastriculcer, and antihepatitis activities. In Vivo: The increase of the lung W/D weight ratios is significantly reduced by high and medium dose of MAG (10 and 30mg/kg) administration. Pretreatment with MAG (10 and 30mg/kg) efficiently reduces the production of TNF-?? and IL-1??. MAG (10, 30mg/kg) significantly decreases NF-??B p65 protein expression, compared with LPS. On the contrary, LPS significantly reduces I??B-?? protein expression compared with the control group, whereas MAG (10 and 30mg/kg) significantly increased I??B-?? expression, compared with the LPS group^[1].
Low- and high-dose MAG treatment significantly reduces the AST, ALT, TBIL, and TBA levels at 14 and 21 d time points when compared with that of the RIF and INH group, suggesting the protective effect of MAG on RIF- and INH-induced liver injury. MAG treatment groups elevate the hepatic GSH level at 7, 14, and 21 d time points and markedly reduce the MDA level at 14 and 21 d time points in RIF- and INH-treated rats, suggesting the protective effect of MAG in RIF- and INH induced liver injuries^[2].